The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.7 billion in 2019.
How this report will benefit you
In this brand new 155-page report you find 64 in-depth tables, charts and graphs – all unavailable elsewhere.
The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.
• This study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies: • Trivalent Influenza Vaccines (TIV) • Quadrivalent Influenza Vaccines (QIV)
• Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share • AstraZeneca • GlaxoSmithKline • Sanofi Pasteur • Seqirus • Others
• Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses: • Seasonal Influenza vaccines in development • Universal Influenza vaccines in development
• The report includes forecasts to 2029 and analysis of pipeline developments for the following specific vaccines: • Fluzone / VaxiGrip • Seqirus Influenza Vaccines • Fluarix / FluLaval • FluMist / Fluenz • FluBlok • Other
• This study shows you forecasts to 2029 of influenza vaccines in developed and developing regions: • United States • Japan • The EU 5 – Germany, France, United Kingdom, Italy and Spain. • Brazil, Russia, India and China.
• Key Questions Answered by this Report: • What is the current size of the total global influenza vaccines market? How much will this market be worth from 2019-2029? • What are the main drivers and restraints that will shape the overall influenza vaccines market over the next ten years? • What are the main segments within the overall influenza vaccines market? How much will each of these segments be worth for the period 2019-2029? How will the composition of the market change during that time, and why? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for influenza vaccines? What is their current status and how will they develop over the next ten years? What are their forecasts for 2019-2029? • How will political and regulatory factors influence the regional markets? • How will the market shares of the national markets change by 2029, and which geographical region will lead the market in 2029? • Who are the leading companies and what are their prospects over the forecast period? • What are the predictions for existing players and the prospects for new market entrants? • What are the leading vaccines? What are their revenues and latest developments? • What are some of the most prominent influenza vaccines currently in development? • What are the main trends that will affect the influenza vaccines market between 2019 and 2029? • What are the main strengths, weaknesses, opportunities and threats for the market? • What are the social, technological, economic and political influences that will shape that industry over the next ten years? • How will the global influenza vaccines market evolve over the forecasted period, 2019-2029? Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.
Buy our report today Influenza Vaccines Market Analysis: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Global Influenza Vaccine Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Influenza Vaccine Market
2.1 What is Influenza?
2.2 Bird Flu
2.3 The Influenza Virus Kills over 500,000 People Every Year
2.4 2018-2019 Vaccine
2.5 Influenza has a Huge Social and Economic Burden on all Societies
2.6 The Influenza Virus Mutates Annually Rendering the Previous Year’s Vaccines Ineffective
2.6.1 Influenza A
2.6.2 Influenza B
2.6.3 Influenza C
2.6.4 All Current Influenza Vaccines are either Trivalent (TIV) or Quadrivalent (QIV)
2.7 Types of Influenza Vaccines
2.7.1 The Flu Shot
2.7.2 Quadrivalent flu vaccine
2.7.3 Intradermal Influenza Vaccines
2.7.4 High-Dose Influenza Vaccines
2.7.5 Cell based Flu vaccines
2.7.6 Recombinant Influenza Vaccines
2.7.7 Flu Vaccination by jet injectors
2.7.8 Adjuvanted Vaccines
2.7.9 Live attenuated Influenza Vaccine (LAIV)/Nasal Spray Vaccines
3. Influenza Vaccine by technology
3.1 Egg-Based Flu Vaccine
3.2 Cell-Based Flu Vaccines
3.3 Recombinant Flu Vaccines
3.3.1 Fact Sheets of recombinant Influenza Vaccine Flublok
3.4 The Antigenic Drift Mutation Causes Epidemics
3.5 The Antigenic Shift Mutation Causes Pandemics
3.6 An Epidemic or a Pandemic Outbreak?
3.7 Seasonal Influenza Epidemic (Local)
3.8 Pandemic Influenza (Worldwide): ‘A’ Subtype
3.9 Flu Vaccine Effectiveness
3.10 Key Influencers of the Influenza Vaccine Market
3.10.1 Governments and International Organisations
3.10.1.1 Every Year the World Health Organisation Identifies the Most Likely Strain of the Influenza Virus
3.10.1.2 The Governmental Stance of the Importance of Influenza Directly Drives the Market
3.10.2 The WHO’s “Influenza Vaccine Production Transfer Project” Affects Big Pharma’s Vaccine Sales
4. Leading Manufacturers
4.1 Sanofi Pasteur
4.1.1 Market Leader
4.2 Seqirus
4.2.1 CSL Has Bought Novartis's Flu Vaccine Business Forming a New Influenza Vaccine Company Seqirus
4.3 Glaxo SmithKline
4.3.1 GSK is Now Third Placed in the Market
4.4 AstraZeneca
4.4.1 AstraZeneca’s Flumist Product is in Trouble
4.5 Abbott Laboratories
4.6 Sinovac Biotech
5. Influenza Vaccine World Market Outlook, 2019-2029
5.1 The World Influenza Market Performance, 2018
5.1.1 Growing Elderly Population
5.1.2 Paediatric Influenza Vaccines – High Demand Markets
5.1.3 Emerging Markets
5.2 The World Influenza Market Revenue Forecast for 2019-2029
5.3 The World Influenza Market: Industry Trends, 2019-2029
5.3.1 Demand Driven Trends
5.3.2 Supply Efficiency Affects Sales
5.3.3 Funding Trends
5.3.4 Protecting the Workforce of an Economy
5.4 TIV Vaccines will be replaced by QIV Vaccines in the Near Future
5.4.1 Trivalent Influenza Vaccines (TIV)
5.4.2 Quadrivalent Influenza Vaccines (QIV)
5.4.3 Influenza Vaccines by TIV and QIV Type
6. Global Influenza Vaccines Market by Vaccine Technology 2019-2029
6.1 The Influenza Vaccine Market Forecast 2019-2029 by Vaccine Technology (Trivalent and Quadrivalent)
Table 5.2 The World Market for Influenza Vaccines by Pharmaceutical Companies and ‘Others’; Revenue Forecast ($m), AGR (%) Market Share (%), 2018- 2029
Table 5.3 Influenza Vaccines Divided into TIV and QIV Type, 2018
Table 6.1 The Influenza Vaccine Revenue Forecast ($m), Annual Growth (%), CAGR (%) by Vaccine Technology, 2019-2029
Table 7.1 Leading Influenza Vaccines: Revenues ($m), 2018
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
